BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat 2020;52:100713. [PMID: 32615525 DOI: 10.1016/j.drup.2020.100713] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Farouk F, Elmaaty AA, Elkamhawy A, Tawfik HO, Alnajjar R, Abourehab MAS, Saleh MA, Eldehna WM, Al-Karmalawy AA. Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies. J Enzyme Inhib Med Chem 2023;38:2171029. [PMID: 36701269 DOI: 10.1080/14756366.2023.2171029] [Reference Citation Analysis]
2 Liu X, Yu J, Luo Y, Dong H. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK-3β inhibitors. Chem Biol Drug Des 2023;101:326-39. [PMID: 35762873 DOI: 10.1111/cbdd.14111] [Reference Citation Analysis]
3 Seo MJ, Kim IY, Lee DM, Park YJ, Cho MY, Jin HJ, Choi KS. Dual inhibition of thioredoxin reductase and proteasome is required for auranofin-induced paraptosis in breast cancer cells. Cell Death Dis 2023;14:42. [PMID: 36658130 DOI: 10.1038/s41419-023-05586-6] [Reference Citation Analysis]
4 Yin W, Chang J, Sun J, Zhang T, Zhao Y, Li Y, Dong H. Nanomedicine-mediated ferroptosis targeting strategies for synergistic cancer therapy. J Mater Chem B 2023. [PMID: 36650960 DOI: 10.1039/d2tb02161g] [Reference Citation Analysis]
5 Rácz B, Spengler G. Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases. Antibiotics (Basel) 2023;12. [PMID: 36671340 DOI: 10.3390/antibiotics12010137] [Reference Citation Analysis]
6 Song B, Kim KJ, Ki SH. Experience with and perceptions of non-prescription anthelmintics for cancer treatments among cancer patients in South Korea: A cross-sectional survey. PLoS One 2022;17:e0275620. [PMID: 36194607 DOI: 10.1371/journal.pone.0275620] [Reference Citation Analysis]
7 Shah S, Famta P, Fernandes V, Bagasariya D, Charankumar K, Kumar Khatri D, Bala Singh S, Srivastava S. Quality by Design steered Development of Niclosamide Loaded Liposomal Thermogel for Melanoma: In vitro and Ex vivo Evaluation. Eur J Pharm Biopharm 2022:S0939-6411(22)00219-3. [PMID: 36198344 DOI: 10.1016/j.ejpb.2022.09.024] [Reference Citation Analysis]
8 Bahadur S, Kumar P. Deep Learning Framework for Cancer Diagnosis and Treatment. Deep Learning for Targeted Treatments 2022. [DOI: 10.1002/9781119857983.ch8] [Reference Citation Analysis]
9 Weng N, Zhang Z, Tan Y, Zhang X, Wei X, Zhu Q. Repurposing antifungal drugs for cancer therapy. J Adv Res 2022:S2090-1232(22)00199-0. [PMID: 36067975 DOI: 10.1016/j.jare.2022.08.018] [Reference Citation Analysis]
10 Seo MJ, Lee DM, Jin HJ, Choi KS. Auranofin induces paraptosis by dual inhibition of thioredoxin reductase and proteasome in breast cancer cells.. [DOI: 10.21203/rs.3.rs-1947663/v1] [Reference Citation Analysis]
11 Panossian A, Efferth T. Network Pharmacology of Adaptogens in the Assessment of Their Pleiotropic Therapeutic Activity. Pharmaceuticals 2022;15:1051. [DOI: 10.3390/ph15091051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Shadyro O, Sosnovskaya A, Edimecheva I, Ihnatovich L, Dubovik B, Krasny S, Tzerkovsky D, Protopovich E. In Vivo Antitumoral Effects of Linseed Oil and Its Combination With Doxorubicin. Front Pharmacol 2022;13:882197. [DOI: 10.3389/fphar.2022.882197] [Reference Citation Analysis]
13 Vale N. Editorial on the Special Issue: "Multidrug Combinations". Biomolecules 2022;12:812. [PMID: 35740937 DOI: 10.3390/biom12060812] [Reference Citation Analysis]
14 Cui Q, Wang C, Zeng L, Zhou Q, Fan Y. Editorial: Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers. Front Chem 2022;10:921985. [DOI: 10.3389/fchem.2022.921985] [Reference Citation Analysis]
15 Sajid A, Lusvarghi S, Ambudkar SV. THE P‐GLYCOPROTEIN MULTIDRUG TRANSPORTER. Drug Transporters 2022. [DOI: 10.1002/9781119739883.ch10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Capobianco E. High-dimensional role of AI and machine learning in cancer research. Br J Cancer 2022;126:523-32. [PMID: 35013580 DOI: 10.1038/s41416-021-01689-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
17 Xu P, Zhang S, Tan L, Wang L, Yang Z, Li J. Local Anesthetic Ropivacaine Exhibits Therapeutic Effects in Cancers. Front Oncol 2022;12:836882. [PMID: 35186766 DOI: 10.3389/fonc.2022.836882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, Zhang L, Ouyang L, Liu B, Yu H. Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions. Acta Pharm Sin B 2022;12:532-57. [PMID: 35256933 DOI: 10.1016/j.apsb.2021.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
19 Singh I, Luxami V, Choudhury D, Paul K. Synthesis and photobiological applications of naphthalimide-benzothiazole conjugates: cytotoxicity and topoisomerase IIα inhibition. RSC Adv 2021;12:483-97. [PMID: 35424470 DOI: 10.1039/d1ra04148g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Yalcin-Ozkat G. Molecular Modeling Strategies of Cancer Multidrug Resistance. Drug Resist Updat 2021;:100789. [PMID: 34973929 DOI: 10.1016/j.drup.2021.100789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kumbhar P, Manjappa A, Shah R, Jha NK, Singh SK, Dua K, Disouza J, Patravale V. Inhalation delivery of repurposed drugs for lung cancer: Approaches, benefits and challenges. J Control Release 2021;341:1-15. [PMID: 34780880 DOI: 10.1016/j.jconrel.2021.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Duarte D, Vale N. Combining repurposed drugs to treat colorectal cancer. Drug Discov Today 2021:S1359-6446(21)00406-2. [PMID: 34592446 DOI: 10.1016/j.drudis.2021.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Galina AC, Sarzi D, de Medeiros LC, Sampaio ALF, Leta J. The promising drugs included in WHO's Solidarity Project: a choice based in scientific knowledge and institutional competencies. Mem Inst Oswaldo Cruz 2021;116:e200603. [PMID: 34495083 DOI: 10.1590/0074-02760200603] [Reference Citation Analysis]
24 Pressley M, Salvioli M, Lewis DB, Richards CL, Brown JS, Staňková K. Evolutionary Dynamics of Treatment-Induced Resistance in Cancer Informs Understanding of Rapid Evolution in Natural Systems. Front Ecol Evol 2021;9:681121. [DOI: 10.3389/fevo.2021.681121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Chen Y, Wu J, Deng Y, Wu Y, Wang X, Li AS, Wong LY, Fu X, Yu Z, Liang C. Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models. Journal of Ginseng Research 2021. [DOI: 10.1016/j.jgr.2021.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Wang R. Anticancer activities, structure-activity relationship, and mechanism of action of 12-, 14-, and 16-membered macrolactones. Arch Pharm (Weinheim) 2021;354:e2100025. [PMID: 34138486 DOI: 10.1002/ardp.202100025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Tilija Pun N, Jeong CH. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance. Pharmaceuticals (Basel) 2021;14:470. [PMID: 34065757 DOI: 10.3390/ph14050470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
28 Rebelo R, Polónia B, Santos LL, Vasconcelos MH, Xavier CPR. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals (Basel) 2021;14:280. [PMID: 33804613 DOI: 10.3390/ph14030280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Gasmi A, Peana M, Arshad M, Butnariu M, Menzel A, Bjørklund G. Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis. Arch Toxicol 2021;95:1161-78. [DOI: 10.1007/s00204-021-02974-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
30 Martinez-Escobar A, Luna-Callejas B, Ramón-Gallegos E. CRISPR-dCas9-Based Artificial Transcription Factors to Improve Efficacy of Cancer Treatment With Drug Repurposing: Proposal for Future Research. Front Oncol 2020;10:604948. [PMID: 33614489 DOI: 10.3389/fonc.2020.604948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Migliore R, Granata G, Rivoli A, Consoli GML, Sgarlata C. Binding Affinity and Driving Forces for the Interaction of Calixarene-Based Micellar Aggregates With Model Antibiotics in Neutral Aqueous Solution. Front Chem 2020;8:626467. [PMID: 33520941 DOI: 10.3389/fchem.2020.626467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
32 Monk BC, Keniya MV. Roles for Structural Biology in the Discovery of Drugs and Agrochemicals Targeting Sterol 14α-Demethylases. J Fungi (Basel) 2021;7:67. [PMID: 33498194 DOI: 10.3390/jof7020067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Hernández-Lemus E, Martínez-García M. Pathway-Based Drug-Repurposing Schemes in Cancer: The Role of Translational Bioinformatics. Front Oncol 2020;10:605680. [PMID: 33520715 DOI: 10.3389/fonc.2020.605680] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
34 Peña‐guerrero J, Nguewa PA, García‐sosa AT. Machine learning, artificial intelligence, and data science breaking into drug design and neglected diseases. WIREs Comput Mol Sci 2021;11. [DOI: 10.1002/wcms.1513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
35 Vivarelli S, Candido S, Caruso G, Falzone L, Libra M. Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. Cancers (Basel) 2020;12:E3636. [PMID: 33291603 DOI: 10.3390/cancers12123636] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
36 Galina AC, Sarzi D, de Medeiros LC, Sampaio ALF, Leta J. Scientific output on coronavirus and WHO’s Solidarity Project: a science-based choice?. [DOI: 10.1101/2020.11.16.20232488] [Reference Citation Analysis]
37 Garcia C, Isca VMS, Pereira F, Monteiro CM, Ntungwe E, Sousa F, Dinic J, Holmstedt S, Roberto A, Díaz-Lanza A, Reis CP, Pesic M, Candeias NR, Ferreira RJ, Duarte N, Afonso CAM, Rijo P. Royleanone Derivatives From Plectranthus spp. as a Novel Class of P-Glycoprotein Inhibitors. Front Pharmacol 2020;11:557789. [PMID: 33364937 DOI: 10.3389/fphar.2020.557789] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Harguindey S, Alfarouk K, Polo Orozco J, Fais S, Devesa J. Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era. Int J Mol Sci 2020;21:E7475. [PMID: 33050492 DOI: 10.3390/ijms21207475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Cucchi DGJ, Groen RWJ, Janssen JJWM, Cloos J. Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome. Drug Resist Updat 2020;53:100730. [PMID: 33096284 DOI: 10.1016/j.drup.2020.100730] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]